Welcome to our dedicated page for Arcadia Bioscien SEC filings (Ticker: RKDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arcadia Biosciences, Inc. (Nasdaq: RKDA) SEC filings page on Stock Titan brings together the company’s official regulatory documents, offering a detailed view of how management reports its business, finances, and corporate actions. As a producer and marketer of plant-based and innovative wellness products with a focus on Zola coconut water and related assets, Arcadia uses its filings to describe revenue composition, operating expenses, asset sales, capital structure, and governance matters.
Key filings for RKDA include annual reports on Form 10-K and quarterly reports on Form 10-Q, which provide narrative and tabular disclosures about continuing operations centered on Zola coconut water, discontinued operations related to former brands such as GoodWheat, and the impact of gains on asset sales, credit losses, and changes in fair value of financial instruments. These reports also discuss risk factors, accounting policies, and other items relevant to long-term investors.
Arcadia frequently files current reports on Form 8-K to describe material events. Recent 8-K filings cover topics such as inducement offer letter agreements for the exercise of preferred investment options, the issuance of new preferred investment options and placement agent options, scheduling of the 2025 annual meeting, changes in executive roles, and the previously proposed and later terminated Securities Exchange Agreement with Roosevelt Resources, LP. These documents explain transaction terms, option mechanics, and related covenants.
The company’s proxy materials, including the definitive proxy statement on Schedule 14A, outline director elections, advisory votes on executive compensation, audit firm ratification, and the conduct of virtual stockholder meetings. They also describe board composition, compensation practices, and stockholder voting procedures.
On Stock Titan, RKDA filings are updated as they are made available through EDGAR, and AI-powered summaries help explain the structure and implications of complex documents such as 10-Ks, 10-Qs, 8-Ks, and proxy statements. Investors can quickly scan for disclosures about Arcadia’s wellness-focused operations, Zola coconut water revenues, asset monetization, option and warrant terms, and stockholder meeting matters, while retaining access to the full underlying filings for deeper review.
Arcadia Biosciences, Inc. filed an 8‑K announcing that its audit committee dismissed Deloitte & Touche as independent auditor and appointed Ramirez Jimenez International CPAs (RJI), effective March 30, 2026. Deloitte’s reports on the 2024 and 2025 financial statements included an explanatory paragraph about the company’s ability to continue as a going concern, citing accumulated deficit, recurring net losses, net cash used in operations and limited resources.
The company also reiterates previously disclosed material weaknesses in internal control over financial reporting, including insufficient segregation of duties in the financial close process and insufficient information system controls such as access and change management, driven in part by reduced employee headcount. The 8‑K states there were no disagreements with Deloitte on accounting principles, disclosure, or audit scope, and that Deloitte has been authorized to respond fully to RJI’s inquiries. A confirming letter from Deloitte to the SEC is attached as an exhibit.
Arcadia Biosciences, Inc. reports 2025 product revenue of $4.9M, down slightly as GLA oil sales ended, while Zola coconut water revenue rose 17%. Net loss from continuing operations narrowed to $2.3M from $4.3M in 2024 as operating expenses declined.
The company recorded a $4.7M credit loss after Above Food defaulted on a promissory note from the 2024 GoodWheat sale, partially offset by a $2.0M gain from reducing contingent consideration and a $2.3M gain on AFII stock. Cash and cash equivalents were $0.3M at year-end, and auditors highlighted substantial doubt about Arcadia’s ability to continue as a going concern.
Arcadia has exited wheat trait commercialization and GoodWheat, now focusing on Zola coconut water sourced from Thailand amid evolving U.S. tariff policy. The Roosevelt Resources all-stock combination was terminated with no expected break-up fee, and the company faces a Proposition 65 lawsuit over BPA in canned coconut water and stockholder demand letters related to the terminated Roosevelt transaction.
Arcadia Biosciences reported smaller losses for 2025 but faces liquidity pressure. Total revenues were $4.9M, down slightly from $5.0M, while Zola® coconut water revenues grew 17% year over year. Selling, general and administrative costs fell about 27%, helping reduce net loss attributable to common stockholders to $2.3M from $7.0M.
Cash and cash equivalents dropped to $259K as of December 31, 2025, from $4.2M a year earlier. A proposed business combination with Roosevelt Resources was terminated, and the company raised approximately $2.1M in gross proceeds from the exercise of preferred investment options. Management states it will require additional funding in the near future and may pursue equity or debt financings or asset transactions, which could dilute existing shareholders.
Arcadia Biosciences, Inc. is registering for resale up to 1,673,792 shares of common stock, issuable upon exercise of preferred investment options held by existing investors and placement agents. This includes up to 1,617,190 shares from new Investment Options and 56,602 shares from Placement Agent Options.
The company will not receive proceeds from stockholder resales, but could receive up to approximately $3.94 million if all options are exercised for cash, which it plans to use for working capital and general corporate purposes. Common stock outstanding was 1,729,884 shares as of January 23, 2026, and would be 3,403,676 shares assuming full cash exercise of the Options. Arcadia now focuses on its Zola coconut water brand after selling several legacy crop-related assets, and discloses substantial doubt about its ability to continue as a going concern without additional financing. A previously planned all-stock business combination with Roosevelt Resources, LP has been terminated.
Arcadia Biosciences, Inc. reported that two members of its board of directors, Albert D. Bolles, Ph.D. and Deborah Carosella, resigned from the board effective February 4, 2026.
Bolles served on the Compensation Committee, while Carosella served on both the Compensation Committee and the Nominating and Governance Committee. The company stated that their resignations were not due to any disagreement with the company or its board regarding operations, policies, practices, or financial statements. Both former directors agreed to remain available to assist the company in an advisory capacity.
Arcadia Biosciences, Inc. is registering up to 1,673,792 shares of common stock for resale by selling stockholders. These shares are issuable upon exercise of preferred investment options issued in a January 2026 warrant inducement private placement, including investment options and placement agent options.
The company will not receive proceeds from resale of these shares, but could receive up to approximately $3.94 million if all options are exercised for cash, which it plans to use for working capital and general corporate purposes. Shares outstanding were 1,729,884 as of January 23, 2026, and would be 3,403,676 if all option shares under this prospectus are issued.
Arcadia has shifted from agricultural traits to consumer products and now focuses on its Zola coconut water brand after selling key wheat and GoodWheat assets in 2024. The filing highlights substantial doubt about the company’s ability to continue as a going concern and a need for additional near-term financing. A planned all-stock business combination with Roosevelt Resources was terminated in December 2025, so no merger will proceed under that agreement. The company describes this investment as high risk and notes potential dilution and stock price pressure if large blocks of newly issuable shares are sold.
Arcadia Biosciences entered inducement agreements on January 9, 2026 with certain investors to encourage exercise of existing preferred investment options. Holders agreed to exercise options for 808,595 shares of common stock, with the exercise price cut from $9.00 to $2.575 per share. The closing on January 12, 2026 generated aggregate gross proceeds of about $2.1 million, which the company plans to use for working capital and general corporate purposes.
In exchange, Arcadia issued new unregistered preferred investment options to buy up to 1,617,190 shares at $2.325 per share and placement agent options for 56,602 shares at $3.2188, both exercisable immediately and expiring 30 months after a resale registration statement becomes effective. The new and placement agent options include 4.99% or 9.99% beneficial ownership caps, adjustment provisions, and cashless exercise features if a resale registration is not effective. The company agreed not to issue most additional equity for 45 days after closing and not to enter variable rate transactions for one year.
Arcadia Biosciences, Inc. (RKDA) is asking stockholders to vote at its 2025 annual meeting, to be held virtually on December 19, 2025 at 1:00 p.m. Central Time. Stockholders will be asked to elect three Class I directors (Albert D. Bolles, Kevin Comcowich and CEO Thomas J. Schaefer), approve on an advisory basis the compensation of named executive officers, and ratify Deloitte & Touche LLP as independent registered public accountants for the year ending December 31, 2025.
The meeting is online only, accessible at www.virtualshareholdermeeting.com/RKDA2025 using a 16-digit control number. The Board recommends voting FOR all three proposals. Stockholders of record at the close of business on November 4, 2025, when 1,373,120 shares of common stock were outstanding, are entitled to vote one vote per share. The proxy describes Arcadia’s classified seven‑member board structure, committee memberships, director and executive pay, and ownership levels of directors, officers and key investors.